Role of microRNA-21 in hypertrophic cardiac remodeling

Ken Watanabe,Taro Narumi,Tetsu Watanabe,Yoichiro Otaki,Tetsuya Takahashi,Tomonori Aono,Jun Goto,Taku Toshima,Takayuki Sugai,Masahiro Wanezaki,Daisuke Kutsuzawa,Shigehiko Kato,Harutoshi Tamura,Satoshi Nishiyama,Hiroki Takahashi,Takanori Arimoto,Tetsuro Shishido,Masafumi Watanabe

DOI: https://doi.org/10.1101/850156

2019-11-20

Abstract:Abstract Hypertension is a major public health problem among with aging population worldwide. It causes cardiac remodeling, including hypertrophy and interstitial fibrosis, which leads to development of hypertensive heart disease (HHD). Although microRNA-21 (miR-21) is associated with fibrogenesis in multiple organs, its impact on hypertrophic cardiac remodeling in hypertension is not known. Circulating miR-21 level was higher in patients with HHD than that in the control subjects. It also positively correlated with serum myocardial fibrotic markers. MiR-21 expression levels were significantly upregulated in the mice hearts after angiotensin II (Ang II) infusion or transverse aortic constriction (TAC) compared with control mice. Expression level of programmed cell death 4 (PDCD4), a main target of miR-21, was significantly decreased in Ang II infused mice and TAC mice compared with control mice. Expression levels of transcriptional activator protein 1 (AP-1) and transforming growth factor-β1 (TGF-β1), which were downstream targets of PDCD4, were increased in Ang II infused mice and TAC mice compared with control mice. In vitro , mirVana-miR-21-specific inhibitor attenuated Ang II-induced PDCD4 downregulation and contributed to subsequent deactivation of AP-1/TGF-β1 signaling pathway in neonatal rat cardiomyocytes. Thus, suppression of miR-21 prevents hypertrophic cardiac remodeling by regulating PDCD4, AP-1, and TGF-β1 signaling pathway.